remission induction therapy

remission induction therapy

Oncology Initial chemotherapy administered to a Pt with CA, intended to achieve remission
Mentioned in ?
References in periodicals archive ?
These encouraging results led to the initiation of the Phase III study, POLO-AML-2, investigating volasertib in combination with LDAC, in patients aged 65 years and above with previously untreated AML who are ineligible for intensive remission induction therapy.
today announced the FDA has granted Breakthrough Therapy designation to volasertib*, an investigational inhibitor of polo-like kinase (Plk), being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia (AML), ineligible for intensive remission induction therapy.
Results from a Phase II study, in newly diagnosed patients with AML considered ineligible for intensive remission induction therapy, demonstrated higher rates of objective response and an improvement in event-free survival in patients receiving volasertib in combination with low-dose cytarabine (LDAC) compared to patients receiving LDAC alone.
These data suggest that for limited WG, MTX may be as good a choice as CTX as remission induction therapy.
Based on these data, NanoMed is utilizing Nanotemplate Engineering to develop its lead product which is intended to overcome multidrug resistance in remission induction therapy in elderly acute myelogenous leukemia (AML) patients," Benoit added.
The Phase 3 trial is designed as an open-label, randomized, active control, multi-center study of Xanafide in combination with cytarabine compared to daunorubicin in combination with cytarabine as initial remission induction therapy for patients with sAML.
The study evaluated volasertib in combination with LDAC versus LDAC alone in patients with AML ineligible for intensive remission induction therapy
The current standard of care for remission induction therapy results in poor treatment response rates in many AML patients, especially the elderly and those with secondary AML.
an early-stage specialty pharmaceutical company dedicated to developing improved therapeutic and diagnostic products to treat or detect cancer and other serious diseases, announced that it has achieved its preclinical development milestone for the company's lead oncology product which is intended to overcome multidrug resistance in remission induction therapy in elderly acute myeloid leukemia (AML) patients.
Previous multi-center studies of patients with secondary AML identified remission rates of 24-26% following remission induction therapy with the existing conventional therapy.
The test measures minimal residual disease (MRD) -- the small number of leukemic cells that survive after remission induction therapy.
More than 1,000 children were enrolled across multiple protocols and measured for MRD at day eight and day 28 of remission induction therapy.